BIIB - Latest News

Biogen Inc. (BIIB), operates in Healthcare / Drug Manufacturers - General, trades on NASDAQ.

Market capitalization stands near $30.20B. Trailing twelve-month P/E ratio is 21.94. Beta to the broader market is 0.20.

The article list below shows the most recent BIIB headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent BIIB Headlines

Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB)

prnewswire.com - May 15, 2026

Biogen shares dropped 6. 4% after Phase 2 CELIA trial data revealed information absent from the Company's filings.

Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny - Contact Levi & Korsinsky for Details

newsfilecorp.com - May 15, 2026

New York, New York--(Newsfile Corp. - May 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc.

BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal

zacks.com - May 15, 2026

Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.

Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity

seekingalpha.com - May 15, 2026

Biogen Inc. is upgraded from Sell to Hold, reflecting recent strategic moves and a modest rebound despite persistent structural challenges.

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

marketbeat.com - May 14, 2026

Biogen NASDAQ: BIIB is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected

How News Affects BIIB Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track BIIB's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked BIIB news questions

What is the latest BIIB news headline?

The most recent BIIB headline (May 15, 2026) is "Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB)". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the BIIB news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What BIIB news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual BIIB options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.